Cargando…

Screening for Diabetes and Prediabetes Should Be Cost-Saving in Patients at High Risk

OBJECTIVE: Although screening for diabetes and prediabetes is recommended, it is not clear how best or whom to screen. We therefore compared the economics of screening according to baseline risk. RESEARCH DESIGN AND METHODS: Five screening tests were performed in 1,573 adults without known diabetes—...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Ranee, Narayan, K.M. Venkat, Lipscomb, Joseph, Jackson, Sandra L., Long, Qi, Zhu, Ming, Phillips, Lawrence S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687271/
https://www.ncbi.nlm.nih.gov/pubmed/23393215
http://dx.doi.org/10.2337/dc12-1752
_version_ 1782273894273515520
author Chatterjee, Ranee
Narayan, K.M. Venkat
Lipscomb, Joseph
Jackson, Sandra L.
Long, Qi
Zhu, Ming
Phillips, Lawrence S.
author_facet Chatterjee, Ranee
Narayan, K.M. Venkat
Lipscomb, Joseph
Jackson, Sandra L.
Long, Qi
Zhu, Ming
Phillips, Lawrence S.
author_sort Chatterjee, Ranee
collection PubMed
description OBJECTIVE: Although screening for diabetes and prediabetes is recommended, it is not clear how best or whom to screen. We therefore compared the economics of screening according to baseline risk. RESEARCH DESIGN AND METHODS: Five screening tests were performed in 1,573 adults without known diabetes—random plasma/capillary glucose, plasma/capillary glucose 1 h after 50-g oral glucose (any time, without previous fast, plasma glucose 1 h after a 50-g oral glucose challenge [GCTpl]/capillary glucose 1 h after a 50-g oral glucose challenge [GCTcap]), and A1C—and a definitive 75-g oral glucose tolerance test. Costs of screening included the following: costs of testing (screen plus oral glucose tolerance test, if screen is positive); costs for false-negative results; and costs of treatment of true-positive results with metformin, all over the course of 3 years. We compared costs for no screening, screening everyone for diabetes or high-risk prediabetes, and screening those with risk factors based on age, BMI, blood pressure, waist circumference, lipids, or family history of diabetes. RESULTS: Compared with no screening, cost-savings would be obtained largely from screening those at higher risk, including those with BMI >35 kg/m(2), systolic blood pressure ≥130 mmHg, or age >55 years, with differences of up to −46% of health system costs for screening for diabetes and −21% for screening for dysglycemia(110), respectively (all P < 0.01). GCTpl would be the least expensive screening test for most high-risk groups for this population over the course of 3 years. CONCLUSIONS: From a health economics perspective, screening for diabetes and high-risk prediabetes should target patients at higher risk, particularly those with BMI >35 kg/m(2), systolic blood pressure ≥130 mmHg, or age >55 years, for whom screening can be most cost-saving. GCTpl is generally the least expensive test in high-risk groups and should be considered for routine use as an opportunistic screen in these groups.
format Online
Article
Text
id pubmed-3687271
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-36872712014-07-01 Screening for Diabetes and Prediabetes Should Be Cost-Saving in Patients at High Risk Chatterjee, Ranee Narayan, K.M. Venkat Lipscomb, Joseph Jackson, Sandra L. Long, Qi Zhu, Ming Phillips, Lawrence S. Diabetes Care Original Research OBJECTIVE: Although screening for diabetes and prediabetes is recommended, it is not clear how best or whom to screen. We therefore compared the economics of screening according to baseline risk. RESEARCH DESIGN AND METHODS: Five screening tests were performed in 1,573 adults without known diabetes—random plasma/capillary glucose, plasma/capillary glucose 1 h after 50-g oral glucose (any time, without previous fast, plasma glucose 1 h after a 50-g oral glucose challenge [GCTpl]/capillary glucose 1 h after a 50-g oral glucose challenge [GCTcap]), and A1C—and a definitive 75-g oral glucose tolerance test. Costs of screening included the following: costs of testing (screen plus oral glucose tolerance test, if screen is positive); costs for false-negative results; and costs of treatment of true-positive results with metformin, all over the course of 3 years. We compared costs for no screening, screening everyone for diabetes or high-risk prediabetes, and screening those with risk factors based on age, BMI, blood pressure, waist circumference, lipids, or family history of diabetes. RESULTS: Compared with no screening, cost-savings would be obtained largely from screening those at higher risk, including those with BMI >35 kg/m(2), systolic blood pressure ≥130 mmHg, or age >55 years, with differences of up to −46% of health system costs for screening for diabetes and −21% for screening for dysglycemia(110), respectively (all P < 0.01). GCTpl would be the least expensive screening test for most high-risk groups for this population over the course of 3 years. CONCLUSIONS: From a health economics perspective, screening for diabetes and high-risk prediabetes should target patients at higher risk, particularly those with BMI >35 kg/m(2), systolic blood pressure ≥130 mmHg, or age >55 years, for whom screening can be most cost-saving. GCTpl is generally the least expensive test in high-risk groups and should be considered for routine use as an opportunistic screen in these groups. American Diabetes Association 2013-07 2013-06-12 /pmc/articles/PMC3687271/ /pubmed/23393215 http://dx.doi.org/10.2337/dc12-1752 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Research
Chatterjee, Ranee
Narayan, K.M. Venkat
Lipscomb, Joseph
Jackson, Sandra L.
Long, Qi
Zhu, Ming
Phillips, Lawrence S.
Screening for Diabetes and Prediabetes Should Be Cost-Saving in Patients at High Risk
title Screening for Diabetes and Prediabetes Should Be Cost-Saving in Patients at High Risk
title_full Screening for Diabetes and Prediabetes Should Be Cost-Saving in Patients at High Risk
title_fullStr Screening for Diabetes and Prediabetes Should Be Cost-Saving in Patients at High Risk
title_full_unstemmed Screening for Diabetes and Prediabetes Should Be Cost-Saving in Patients at High Risk
title_short Screening for Diabetes and Prediabetes Should Be Cost-Saving in Patients at High Risk
title_sort screening for diabetes and prediabetes should be cost-saving in patients at high risk
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687271/
https://www.ncbi.nlm.nih.gov/pubmed/23393215
http://dx.doi.org/10.2337/dc12-1752
work_keys_str_mv AT chatterjeeranee screeningfordiabetesandprediabetesshouldbecostsavinginpatientsathighrisk
AT narayankmvenkat screeningfordiabetesandprediabetesshouldbecostsavinginpatientsathighrisk
AT lipscombjoseph screeningfordiabetesandprediabetesshouldbecostsavinginpatientsathighrisk
AT jacksonsandral screeningfordiabetesandprediabetesshouldbecostsavinginpatientsathighrisk
AT longqi screeningfordiabetesandprediabetesshouldbecostsavinginpatientsathighrisk
AT zhuming screeningfordiabetesandprediabetesshouldbecostsavinginpatientsathighrisk
AT phillipslawrences screeningfordiabetesandprediabetesshouldbecostsavinginpatientsathighrisk